Molecular markers in prostate cancer. Part II: potential roles in management

被引：4

作者：

Agrawal, Sachin ^{[1
]}

Patil, Krishnaji P. ^{[1
]}

Dunsmuir, William D. ^{[1
]}

机构：

[1] St Peters Hosp, Dept Urol, Chertsey KT16 0PZ, England

来源：

ASIAN JOURNAL OF ANDROLOGY | 2009年 / 11卷 / 01期

关键词：

genetics; management; molecular; prostate cancer; GROWTH-FACTOR RECEPTOR; SUICIDE GENE-THERAPY; PHASE-I; C-MYC; BONE METASTASIS; CLINICAL-TRIAL; EXPRESSION; CELLS; CARCINOMA; ANTIGEN;

D O I：

10.1038/aja.2008.23

中图分类号：

R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

摘要：

Predicting treatment responses in advanced prostate cancer (PCa) currently centres on prostate-specific antigen (PSA) kinetics and on being able to visualize measurable changes in imaging modalities. New molecular markers have emerged as potential diagnostic and prognostic indicators; these were summarized in Part I of this review in the Asian Journal of Andrology. A number of molecular markers are now being used to enhance PCa imaging and staging. However, management options for advanced and hormone-resistant PCa (HRPC) are limited and additional therapeutic options are needed. Molecular markers have been proposed as potential therapeutic targets using gene therapy and immunomodulation. Additionally, markers identified in early PCa and precursor lesions may offer novel targets for chemoprevention and vaccine development. This review summarizes the current advances regarding the roles of these markers in the management of PCa.

引用

页码：22 / 27

页数：6

共 51 条

[1]

AHN M, 2008, CANC GENE THER 0905

[2] Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: A novel therapy in prostate cancer [J].

Balaji, KC ;

Koul, H ;

Mitra, S ;

Maramag, C ;

Reddy, P ;

Menon, M ;

Malhotra, RK ;

Laxmanan, S .

UROLOGY, 1997, 50 (06) :1007-1015

[3] Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate [J].

Barton, Kenneth N. ;

Stricker, Hans ;

Brown, Stephen L. ;

Elshaikh, Mohamed ;

Aref, Ibrahim ;

Lu, Mei ;

Pegg, Jan ;

Zhang, Yingshu ;

Karvelis, Kastytis C. ;

Siddiqui, Farzan ;

Kim, Jae Ho ;

Freytag, Svend O. ;

Movsas, Benjamin .

MOLECULAR THERAPY, 2008, 16 (10) :1761-1769

[4]

Bauer JJ, 1995, CLIN CANCER RES, V1, P1295

[5] Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy [J].

Berry, W ;

Eisenberger, M .

ONCOLOGIST, 2005, 10 :30-39

[6] A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer [J].

Carducci, Michael A. ;

Saad, Fred ;

Abrahamsson, Per-Anders ;

Dearnaley, David R. ;

Schulman, Claude C. ;

North, Scott A. ;

Sleep, Darryl J. ;

Isaacson, Jeffrey D. ;

Nelson, Joel B. .

CANCER, 2007, 110 (09) :1959-1966

[7] Targeting bone metastasis in prostate cancer with endothelin receptor antagonists [J].

Carducci, Michael A. ;

Jimeno, Antonio .

CLINICAL CANCER RESEARCH, 2006, 12 (20) :6296S-6300S

[8] TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions [J].

Cerveira, Nuno ;

Ribeiro, Franclim R. ;

Peixoto, Ana ;

Costa, Vera ;

Henrique, Rui ;

Jeronimo, Carmen ;

Teixeira, Manuel R. .

NEOPLASIA, 2006, 8 (10) :826-832

[9]

Chan Norman, 2007, Future Oncol, V3, P329, DOI 10.2217/14796694.3.3.329

[10]

CRAWFORD ED, 2008, UPTODATE

← 1 2 3 4 5 6 →